Lupin in news

has signed a definitive licensing and supply deal with European pharmaceutical major Zentiva Group to take its biosimilar Certolizumab Pegol to global markets. This is considered a key step forward in the company’s push to grow its biopharma footprint. Lupin will handle everything from development to manufacturing for Certolizumab Pegol, while Zentiva will take charge of getting the drug to patients across markets outside the US and Canada. The partnership plays to both companies’ strengths, Lupin’s expertise in biosimilar production and Zentiva’s deep regulatory experience and strong commercial presence across Europe and the CIS region. Lupin will directly handle marketing in the USA, Canada, and other global territories outside Zentiva’s scope. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.